David W Noller, MD
Urology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 27
- 7 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Good Samaritan Hospital · Santa Clara Valley Medical Center · 05t308 · 05t380. That is not proof they admit you there this week.
Plans that list them
27 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Noller’s office at (408) 871-5220 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
27 of 27 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence G39344 · Current
Licensed to practise in California · since 1979 · expires 2029-02-28 · University of Washington School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$606,078
Medicare paid this office $606,078 for 429 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 300 | $88,756 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $66,077 | $106 |
| Detection test by nucleic acid for organism, amplified probe technique | 101 | $61,350 | $34 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 102 | $45,100 | $69 |
| Long return visit (40+ min) | 158 | $39,569 | $164 |
See all 41 services
| Return visit (30+ min) | 300 | $88,756 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $66,077 | $106 |
| Detection test by nucleic acid for organism, amplified probe technique | 101 | $61,350 | $34 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 102 | $45,100 | $69 |
| Long return visit (40+ min) | 158 | $39,569 | $164 |
| Short return visit (20+ min) | 174 | $25,303 | $82 |
| Complete ultrasound scan of pelvis | 173 | $24,513 | $109 |
| Limited ultrasound scan of pelvis | 217 | $14,587 | $46 |
| Ultrasound scan of pelvic region through rectum | 82 | $14,329 | $146 |
| Short return visit | 140 | $13,188 | $55 |
| Complete ultrasound scan behind abdominal cavity | 83 | $11,495 | $111 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 54 | $9,755 | $155 |
| Simple measurement of pressure of urine flow in bladder | 24 | $9,320 | $233 |
| Biopsy of bladder using an endoscope | 16 | $8,297 | $377 |
| Detection of mycoplasma genitalium by dna or rna probe | 101 | $7,703 | $34 |
| Detection test for candida species (yeast), amplified probe technique | 102 | $7,703 | $34 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 102 | $7,703 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 101 | $7,669 | $34 |
| Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique | 101 | $7,669 | $34 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 101 | $7,669 | $34 |
| Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique | 101 | $7,669 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 101 | $7,669 | $34 |
| Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique | 100 | $7,635 | $34 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 101 | $7,600 | $34 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 20 | $6,534 | $44 |
| Complicated insertion of bladder tube | 21 | $5,871 | $151 |
| Telephone medical discussion with physician, 11-20 minutes | 50 | $5,532 | $88 |
| Detection test for gardnerella vaginalis (bacteria), amplified probe technique | 57 | $4,987 | $34 |
| Telephone medical discussion with physician, 21-30 minutes | 32 | $4,319 | $117 |
| Urinalysis, manual test | 330 | $2,899 | $3 |
| Ultrasound scan of scrotum | 15 | $2,382 | $104 |
| Limited ultrasound scan behind abdominal cavity | 36 | $2,236 | $56 |
| New patient visit (45+ min) | 14 | $2,225 | $159 |
| New patient visit (60+ min) | 11 | $2,220 | $202 |
| Ultrasound measurement of bladder capacity after voiding | 117 | $2,025 | $12 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,379 | $106 |
| Telephone medical discussion with physician, 5-10 minutes | 24 | $1,340 | $54 |
| Simple measurement of pressure of urine flow in bladder | 14 | $1,196 | $66 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 59 | $1,180 | $15 |
| Manual urinalysis test with examination using microscope, non-automated | 145 | $753 | $4 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 25 | $658 | $24 |
Procedures Medicare counted
| Prostate resection | 1-10 | None |
Who their Medicare patients are
429 Original Medicare patients in 2024. Average age 79 · 85 and older 29% · Women 26% · Also on Medicaid 6% · Health risk score 1.19. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Coronary heart disease 38% · Diabetes 30% · Cancer 29% · Chronic kidney disease 27% · Atrial fibrillation 27% · Heart failure 20% · Stroke 16% · Depression 14% · COPD 13% · Dementia 12%.
The office billed $2,170,714, Medicare allowed $730,537 and paid $606,078; for 11,487 services of 104 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 429 | 11,487 | 79 | 1.19 | $2,170,714 | $606,078 |
| 2023 | 429 | 11,054 | 79 | 1.18 | $1,352,318 | $592,492 |
| 2022 | 451 | 7,105 | 79 | 1.24 | $1,015,494 | $383,613 |
| 2021 | 448 | 8,107 | 79 | 1.19 | $1,177,215 | $441,082 |
| 2020 | 437 | 9,415 | 78 | 1.22 | $1,217,242 | $428,091 |
| 2019 | 503 | 6,768 | 78 | 1.24 | $1,134,315 | $365,605 |
| 2018 | 486 | 5,213 | 77 | 1.19 | $1,020,568 | $316,489 |
| 2017 | 528 | 5,012 | 78 | 1.17 | $1,070,020 | $340,257 |
| 2016 | 577 | 5,542 | 77 | 1.31 | $1,183,010 | $388,881 |
| 2015 | 625 | 5,488 | 77 | 1.26 | $1,126,206 | $392,038 |
| 2014 | 613 | 5,881 | 77 | 1.19 | $1,043,549 | $360,271 |
| 2013 | 652 | 6,996 | 77 | 1.21 | $1,318,917 | $463,186 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 32 services
| Return visit (30+ min) | 369 | $141,079 | $119 |
| Detection test by nucleic acid for organism, amplified probe technique | 128 | $78,646 | $34 |
| Detection test by nucleic acid for multiple organisms, amplified probe(s) technique | 126 | $57,469 | $68 |
| Short return visit (20+ min) | 249 | $50,799 | $86 |
| Limited ultrasound scan of pelvis | 280 | $31,330 | $49 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 43 | $18,844 | $44 |
| Long return visit (40+ min) | 56 | $12,396 | $168 |
| Complete ultrasound scan of pelvis | 87 | $10,753 | $112 |
| Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique | 128 | $9,775 | $34 |
| Detection test for candida species (yeast), amplified probe technique | 128 | $9,741 | $34 |
| Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique | 128 | $9,741 | $34 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 128 | $9,741 | $34 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 128 | $9,741 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 128 | $9,741 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 128 | $9,706 | $34 |
| Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique | 128 | $9,706 | $34 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 127 | $9,672 | $34 |
| Detection of mycoplasma genitalium by dna or rna probe | 118 | $8,672 | $34 |
| Biopsy of bladder using an endoscope | 14 | $6,725 | $396 |
| Limited ultrasound scan behind abdominal cavity | 67 | $5,539 | $60 |
| Detection test for gardnerella vaginalis (bacteria), amplified probe technique | 64 | $5,502 | $34 |
| Complete ultrasound scan behind abdominal cavity | 42 | $5,047 | $115 |
| Ultrasound scan of pelvic region through rectum | 25 | $4,410 | $147 |
| Manual urinalysis test with examination using microscope, non-automated | 371 | $4,336 | $4 |
| Ultrasound scan of scrotum | 15 | $3,644 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,594 | $156 |
| Simple measurement of pressure of urine flow in bladder | 13 | $3,190 | $228 |
| Diagnostic exam of bladder and urethra using an endoscope | 12 | $3,027 | $252 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $2,894 | $107 |
| Complicated insertion of bladder tube | 11 | $2,026 | $145 |
| Short return visit | 26 | $1,343 | $48 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 43 | $1,082 | $22 |
2022: 30 services
| Return visit (30+ min) | 372 | $130,550 | $116 |
| Limited ultrasound scan of pelvis | 298 | $33,031 | $48 |
| Short return visit (20+ min) | 136 | $19,559 | $72 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 40 | $13,896 | $35 |
| Short return visit | 167 | $12,386 | $49 |
| Biopsy of bladder using an endoscope | 22 | $11,763 | $406 |
| Long return visit (40+ min) | 54 | $10,954 | $166 |
| Complete ultrasound scan behind abdominal cavity | 75 | $9,651 | $116 |
| Detection test by nucleic acid for organism, amplified probe technique | 22 | $8,666 | $34 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 19 | $8,632 | $332 |
| Complicated insertion of bladder tube | 21 | $7,555 | $151 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,010 | $179 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 142 | $4,972 | $23 |
| Manual urinalysis test with examination using microscope, non-automated | 382 | $4,622 | $4 |
| Simple measurement of pressure of urine flow in bladder | 17 | $4,530 | $189 |
| Limited ultrasound scan behind abdominal cavity | 49 | $3,761 | $58 |
| Ultrasound scan of pelvic region through rectum | 20 | $3,326 | $151 |
| Complete ultrasound scan of pelvis | 26 | $3,061 | $113 |
| Ultrasound scan of scrotum | 18 | $3,035 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $2,413 | $93 |
| Detection test for candida species (yeast), amplified probe technique | 22 | $997 | $34 |
| Detection test by nucleic acid for chlamydia trachomatis, amplified probe technique | 22 | $997 | $34 |
| Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | 22 | $997 | $34 |
| Detection test by nucleic acid for neisseria gonorrhoeae (gonorrhoeae bacteria), amplified probe technique | 22 | $997 | $34 |
| Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | 22 | $997 | $34 |
| Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | 22 | $997 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | 22 | $997 | $34 |
| Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | 22 | $997 | $34 |
| Detection test by nucleic acid for trichomonas vaginalis (genital parasite), amplified probe technique | 22 | $997 | $34 |
| Electronic assessment of bladder emptying | 11 | $86 | $7 |
2021: 23 services
| Return visit (30+ min) | 383 | $140,885 | $119 |
| Short return visit (20+ min) | 221 | $39,509 | $78 |
| Limited ultrasound scan of pelvis | 336 | $38,276 | $48 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 55 | $18,561 | $35 |
| Biopsy of bladder using an endoscope | 33 | $16,053 | $422 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $12,174 | None |
| Complete ultrasound scan behind abdominal cavity | 82 | $11,676 | $118 |
| Long return visit (40+ min) | 54 | $11,429 | $166 |
| Short return visit | 136 | $9,938 | $49 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 17 | $7,437 | $323 |
| Complicated insertion of bladder tube | 21 | $7,007 | $152 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,310 | $177 |
| Limited ultrasound scan behind abdominal cavity | 75 | $5,175 | $59 |
| Simple measurement of pressure of urine flow in bladder | 20 | $5,053 | $187 |
| Manual urinalysis test with examination using microscope, non-automated | 392 | $4,955 | $4 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 30 | $3,212 | $94 |
| Diagnostic exam of bladder and urethra using an endoscope | 11 | $2,999 | $250 |
| Simple measurement of pressure of urine flow in bladder | 25 | $2,421 | $69 |
| Ultrasound scan of scrotum | 12 | $2,100 | $111 |
| Subsequent dilation of stricture of urethra in male by passage of dilator | 17 | $1,958 | $85 |
| Complete ultrasound scan of pelvis | 15 | $1,761 | $117 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $1,027 | $33 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 37 | $850 | $22 |
2020: 25 services
| Return visit (30+ min) | 377 | $136,761 | $99 |
| Limited ultrasound scan of pelvis | 341 | $38,877 | $47 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 18 | $26,717 | None |
| Short return visit (20+ min) | 157 | $25,165 | $71 |
| Biopsy of bladder using an endoscope | 27 | $13,012 | $394 |
| Long return visit (40+ min) | 56 | $9,296 | $139 |
| Limited ultrasound scan behind abdominal cavity | 99 | $9,228 | $58 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 23 | $9,103 | $294 |
| Ultrasound scan of pelvic region through rectum | 44 | $8,210 | $144 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 28 | $6,538 | $36 |
| Simple measurement of pressure of urine flow in bladder | 25 | $6,112 | $170 |
| Complicated insertion of bladder tube | 24 | $5,284 | $139 |
| Manual urinalysis test with examination using microscope, non-automated | 392 | $4,870 | $4 |
| Diagnostic exam of bladder and urethra using an endoscope | 16 | $3,934 | $219 |
| Ultrasound scan of scrotum | 23 | $3,694 | $109 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,790 | $186 |
| Biopsy of prostate gland | 11 | $2,739 | $249 |
| Complete ultrasound scan of pelvis | 22 | $2,528 | $115 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $1,918 | $96 |
| Complete ultrasound scan behind abdominal cavity | 15 | $1,843 | $115 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $1,741 | $32 |
| Subsequent dilation of stricture of urethra in male by passage of dilator | 16 | $1,667 | $79 |
| Short return visit | 23 | $1,336 | $45 |
| Imaging of urinary tract following injection of a contrast agent | 11 | $258 | $23 |
| Ultrasound measurement of bladder capacity after voiding | 16 | $211 | $11 |
2019: 26 services
| Return visit (30+ min) | 424 | $121,830 | $97 |
| Limited ultrasound scan of pelvis | 393 | $41,566 | $46 |
| Biopsy of bladder using an endoscope | 33 | $17,304 | $376 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 56 | $16,553 | $35 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $15,062 | None |
| Ultrasound scan of pelvic region through rectum | 63 | $11,594 | $133 |
| Limited ultrasound scan behind abdominal cavity | 106 | $9,384 | $58 |
| Short return visit (20+ min) | 46 | $8,411 | $67 |
| Simple measurement of pressure of urine flow in bladder | 27 | $6,906 | $197 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,761 | $183 |
| Manual urinalysis test with examination using microscope, non-automated | 439 | $5,219 | $4 |
| Complicated insertion of bladder tube | 16 | $4,346 | $128 |
| Complete ultrasound scan behind abdominal cavity | 38 | $4,309 | $113 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $3,381 | $94 |
| Long return visit (40+ min) | 22 | $3,362 | $129 |
| Complete ultrasound scan of pelvis | 27 | $2,888 | $107 |
| Ultrasound scan of scrotum | 23 | $2,778 | $103 |
| Biopsy of prostate gland | 11 | $2,733 | $248 |
| Subsequent dilation of stricture of urethra in male by passage of dilator | 19 | $2,010 | $77 |
| Simple measurement of pressure of urine flow in bladder | 19 | $1,734 | $69 |
| Initial dilation of urethra in male using dilator | 15 | $1,271 | $79 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $893 | $30 |
| Ultrasound measurement of bladder capacity after voiding | 43 | $677 | $13 |
| Ultrasonic guidance for needle placement | 11 | $615 | $56 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $484 | $23 |
| Manual urinalysis test with examination using microscope, automated | 12 | $52 | $3 |
2018: 23 services
| Return visit (30+ min) | 418 | $100,087 | $91 |
| Limited ultrasound scan of pelvis | 361 | $30,984 | $44 |
| Biopsy of bladder using an endoscope | 30 | $17,221 | $366 |
| Short return visit (20+ min) | 136 | $16,962 | $59 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $14,880 | None |
| Complete ultrasound scan behind abdominal cavity | 107 | $12,238 | $106 |
| Dilation of urethra using an endoscope | 20 | $11,276 | $262 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $9,172 | $91 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 26 | $6,411 | $34 |
| Limited ultrasound scan behind abdominal cavity | 74 | $6,127 | $53 |
| Simple measurement of pressure of urine flow in bladder | 27 | $5,959 | $175 |
| Ultrasound scan of pelvic region through rectum | 41 | $5,352 | $94 |
| Manual urinalysis test with examination using microscope, non-automated | 446 | $5,094 | $4 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,764 | $176 |
| Complicated insertion of bladder tube | 15 | $4,003 | $118 |
| Long return visit (40+ min) | 23 | $3,235 | $116 |
| Diagnostic exam of bladder and urethra using an endoscope | 16 | $2,795 | $155 |
| Complete ultrasound scan of pelvis | 24 | $2,592 | $104 |
| Subsequent dilation of stricture of urethra in male by passage of dilator | 23 | $2,030 | $75 |
| Ultrasound scan of scrotum | 18 | $1,569 | $60 |
| Ultrasound measurement of bladder capacity after voiding | 63 | $1,401 | $16 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $1,284 | $30 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 16 | $357 | $19 |
2017: 28 services
| Return visit (30+ min) | 358 | $60,755 | $96 |
| Long return visit (40+ min) | 212 | $43,072 | $115 |
| Short return visit (20+ min) | 233 | $31,524 | $68 |
| Limited ultrasound scan of pelvis | 285 | $24,429 | $46 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $21,264 | None |
| Complete ultrasound scan behind abdominal cavity | 137 | $19,192 | $114 |
| Dilation of urethra using an endoscope | 29 | $14,644 | $266 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 47 | $10,234 | $35 |
| Biopsy of bladder using an endoscope | 20 | $9,674 | $372 |
| Complete ultrasound scan of pelvis | 82 | $8,915 | $107 |
| Simple measurement of pressure of urine flow in bladder | 26 | $6,469 | $185 |
| Manual urinalysis test with examination using microscope, non-automated | 481 | $5,731 | $4 |
| Diagnostic exam of bladder and urethra using an endoscope | 26 | $5,668 | $162 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,397 | $180 |
| Ultrasound measurement of bladder capacity after voiding | 142 | $4,115 | $20 |
| Ultrasound scan of pelvic region through rectum | 34 | $4,043 | $94 |
| Complicated insertion of bladder tube | 20 | $3,955 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $2,430 | $93 |
| Limited ultrasound scan behind abdominal cavity | 25 | $2,416 | $58 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $1,734 | $32 |
| Initial dilation of urethra in male using filiform dilator | 15 | $1,646 | $110 |
| Subsequent dilation of urethral stricture in male by passage of filiform urethral dilator | 11 | $1,411 | $101 |
| Ultrasound scan of scrotum | 13 | $1,167 | $65 |
| Subsequent dilation of stricture of urethra in male by passage of dilator | 13 | $1,013 | $78 |
| Ultrasonic guidance for needle placement | 11 | $766 | $59 |
| Electronic assessment of bladder emptying | 23 | $367 | $15 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $241 | $20 |
| Imaging of urinary tract following injection of a contrast agent | 11 | $177 | $16 |
2016: 27 services
| Long return visit (40+ min) | 362 | $117,233 | $117 |
| Return visit (30+ min) | 190 | $49,075 | $91 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $19,872 | None |
| Complete ultrasound scan of pelvis | 153 | $17,261 | $105 |
| Dilation of urethra using an endoscope | 33 | $15,838 | $251 |
| Complete ultrasound scan behind abdominal cavity | 112 | $15,165 | $109 |
| Limited ultrasound scan of pelvis | 230 | $14,441 | $44 |
| Biopsy of bladder using an endoscope | 23 | $13,014 | $352 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 42 | $9,079 | $34 |
| Ultrasound measurement of bladder capacity after voiding | 249 | $7,469 | $19 |
| Short return visit (20+ min) | 56 | $7,276 | $61 |
| Manual urinalysis test with examination using microscope, non-automated | 514 | $6,677 | $4 |
| Diagnostic exam of bladder and urethra using an endoscope | 33 | $6,549 | $187 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $5,759 | $169 |
| Simple measurement of pressure of urine flow in bladder | 26 | $5,290 | $176 |
| Ultrasound scan of pelvic region through rectum | 43 | $4,858 | $90 |
| Subsequent dilation of urethra in female | 28 | $4,202 | $64 |
| Biopsy of prostate gland | 20 | $4,189 | $199 |
| Initial dilation of urethra in male using filiform dilator | 25 | $3,016 | $104 |
| Limited ultrasound scan behind abdominal cavity | 29 | $2,064 | $53 |
| Ultrasound scan of scrotum | 21 | $2,036 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $1,690 | $89 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $1,685 | $31 |
| Ultrasonic guidance for needle placement | 21 | $1,413 | $57 |
| Subsequent dilation of stricture of urethra in male by passage of dilator | 17 | $1,294 | $72 |
| Electronic assessment of bladder emptying | 29 | $413 | $14 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 14 | $301 | $18 |
2015: 32 services
| Long return visit (40+ min) | 380 | $116,289 | $125 |
| Return visit (30+ min) | 188 | $46,263 | $94 |
| Dilation of urethra using an endoscope | 62 | $24,452 | $260 |
| Diagnostic exam of bladder and urethra using an endoscope | 76 | $18,207 | $194 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $15,723 | None |
| Biopsy of bladder using an endoscope | 27 | $13,474 | $364 |
| Ultrasound measurement of bladder capacity after voiding | 367 | $12,761 | $19 |
| Complete ultrasound scan of pelvis | 85 | $10,232 | $109 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 39 | $8,972 | $35 |
| Short return visit (20+ min) | 58 | $8,334 | $63 |
| Simple measurement of pressure of urine flow in bladder | 36 | $8,010 | $170 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,992 | $179 |
| Complete ultrasound scan behind abdominal cavity | 60 | $6,792 | $111 |
| Manual urinalysis test with examination using microscope, non-automated | 561 | $6,548 | $4 |
| Subsequent dilation of urethra in female | 42 | $6,064 | $65 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 22 | $5,159 | $224 |
| Ultrasound scan of pelvic region through rectum | 40 | $4,098 | $91 |
| Limited ultrasound scan behind abdominal cavity | 46 | $3,386 | $54 |
| New patient visit (45+ min) | 22 | $3,287 | $149 |
| Irrigation and removal of multiple blood clots from bladder and urethra using an endoscope | 13 | $3,192 | $246 |
| Limited ultrasound scan of pelvis | 46 | $2,608 | $46 |
| Subsequent dilation of stricture of urethra in male by passage of dilator | 25 | $2,596 | $76 |
| Cell examination of specimen, selective cellular enhancement technique | 42 | $1,616 | $32 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $1,430 | $32 |
| Ultrasound scan of scrotum | 17 | $1,408 | $64 |
| Simple measurement of pressure of urine flow in bladder | 18 | $1,357 | $68 |
| Electronic assessment of bladder emptying | 80 | $1,330 | $15 |
| Initial dilation of urethra in male using dilator | 14 | $1,054 | $75 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,013 | $92 |
| Short return visit | 15 | $1,000 | $40 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $233 | $19 |
| Imaging of urinary tract following injection of a contrast agent | 12 | $192 | $16 |
2014: 30 services
| Return visit (30+ min) | 319 | $53,887 | $97 |
| Short return visit (20+ min) | 370 | $38,846 | $61 |
| Long return visit (40+ min) | 167 | $31,392 | $130 |
| Dilation of urethra using an endoscope | 66 | $21,390 | $252 |
| Diagnostic exam of bladder and urethra using an endoscope | 94 | $20,266 | $183 |
| Biopsy of bladder using an endoscope | 35 | $19,039 | $359 |
| Ultrasound measurement of bladder capacity after voiding | 412 | $15,439 | $19 |
| Complete ultrasound scan behind abdominal cavity | 72 | $10,096 | $129 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $9,336 | None |
| New patient visit (45+ min) | 59 | $7,558 | $128 |
| Complete ultrasound scan of pelvis | 62 | $7,471 | $120 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 29 | $7,175 | $224 |
| Irrigation and removal of multiple blood clots from bladder and urethra using an endoscope | 15 | $6,457 | $340 |
| Manual urinalysis test with examination using microscope, non-automated | 555 | $6,109 | $4 |
| Limited ultrasound scan of pelvis | 67 | $3,833 | $49 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 20 | $3,782 | $35 |
| Simple measurement of pressure of urine flow in bladder | 18 | $3,696 | $154 |
| Subsequent dilation of urethra in female | 34 | $3,410 | $62 |
| Limited ultrasound scan behind abdominal cavity | 44 | $3,368 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,878 | $180 |
| Ultrasound scan of pelvic region through rectum | 31 | $2,788 | $77 |
| Electronic assessment of bladder emptying | 126 | $2,087 | $13 |
| Complete ultrasound scan of abdomen | 11 | $1,523 | $138 |
| Ultrasound scan of scrotum | 20 | $1,242 | $54 |
| Short return visit | 26 | $1,225 | $40 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $1,213 | $32 |
| Subsequent dilation of stricture of urethra in male by passage of dilator | 11 | $1,065 | $76 |
| Simple measurement of pressure of urine flow in bladder | 11 | $782 | $56 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 26 | $626 | $20 |
| Cell examination of specimen, selective cellular enhancement technique | 11 | $363 | $33 |
2013: 33 services
| Short return visit (20+ min) | 524 | $96,616 | $66 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 24 | $30,487 | None |
| Complete ultrasound scan behind abdominal cavity | 178 | $28,164 | $132 |
| Diagnostic exam of bladder and urethra using an endoscope | 109 | $25,964 | $182 |
| Complete ultrasound scan of pelvis | 179 | $24,279 | $120 |
| Dilation of urethra using an endoscope | 66 | $20,338 | $245 |
| Biopsy of bladder using an endoscope | 38 | $17,154 | $357 |
| Return visit (30+ min) | 142 | $16,591 | $96 |
| Limited ultrasound scan of pelvis | 174 | $16,233 | $76 |
| Simple measurement of pressure of urine flow in bladder | 66 | $15,050 | $157 |
| New patient visit (45+ min) | 98 | $14,137 | $144 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 31 | $10,144 | $221 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 37 | $9,661 | $34 |
| Ultrasound measurement of bladder capacity after voiding | 283 | $9,468 | $20 |
| Manual urinalysis test with examination using microscope, non-automated | 592 | $7,227 | $4 |
| Shock wave crushing of kidney stones | 11 | $6,477 | $498 |
| Subsequent dilation of urethra in female | 50 | $5,672 | $62 |
| Ultrasound scan of scrotum | 30 | $5,590 | $119 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $5,283 | $176 |
| Long return visit (40+ min) | 38 | $5,121 | $128 |
| Limited ultrasound scan behind abdominal cavity | 46 | $5,078 | $98 |
| Ultrasonic guidance for needle placement | 18 | $4,922 | $214 |
| Ultrasound scan of pelvic region through rectum | 50 | $4,219 | $65 |
| Biopsy of prostate gland | 16 | $3,473 | $204 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 26 | $3,287 | $33 |
| Simple measurement of pressure of urine flow in bladder | 19 | $2,171 | $66 |
| Electronic assessment of bladder emptying | 122 | $2,171 | $14 |
| Subsequent dilation of stricture of urethra in male by passage of dilator | 18 | $1,823 | $76 |
| Manipulation of stone in ureter using an endoscope | 11 | $1,361 | $113 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 51 | $1,245 | $19 |
| Short return visit | 14 | $716 | $42 |
| Cell examination of specimen, selective cellular enhancement technique | 13 | $697 | $54 |
| Cell examination of specimen, concentration technique | 11 | $618 | $56 |
Drugs they prescribed that Part D paid
$284,222
Pharmacies billed $284,222 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (55 of 1,859) in 2024. Above the middle of the specialty; the typical urology clinician is at 2%.
1,642 generic and 217 brand-name prescriptions · $284,222 in drug cost · 315 antibiotic prescriptions to 132 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gemtesa | 101 | $114,067 | $1,129 |
| Myrbetriq | 78 | $81,460 | $1,044 |
| Silodosin | 113 | $11,560 | $102 |
| Testosterone | 58 | $10,344 | $178 |
| Tamsulosin | 357 | $6,630 | $19 |
See all 29 drugs
| Gemtesa | 101 | $114,067 | $1,129 |
| Myrbetriq | 78 | $81,460 | $1,044 |
| Silodosin | 113 | $11,560 | $102 |
| Testosterone | 58 | $10,344 | $178 |
| Tamsulosin | 357 | $6,630 | $19 |
| Dutasteride | 123 | $5,832 | $47 |
| Tadalafil | 35 | $5,419 | $155 |
| Estradiol | 83 | $5,153 | $62 |
| Bethanechol Chloride | 52 | $4,708 | $91 |
| Finasteride | 150 | $2,355 | $16 |
| Nitrofurantoin Mono-Macro | 72 | $2,101 | $29 |
| Solifenacin | 29 | $1,443 | $50 |
| Desmopressin Acetate | 11 | $1,255 | $114 |
| Tolterodine Tartrate Er | 15 | $1,204 | $80 |
| Doxazosin Mesylate | 37 | $1,165 | $31 |
| Fesoterodine Fumarate Er | 11 | $860 | $78 |
| Ciprofloxacin | 120 | $779 | $6 |
| Hydrocodone-Acetaminophen | 52 | $672 | $13 |
| Nitrofurantoin | 20 | $476 | $24 |
| Bicalutamide | 13 | $463 | $36 |
| Clobetasol Propionate | 20 | $458 | $23 |
| Oxybutynin Chloride Er | 24 | $425 | $18 |
| Cephalexin | 26 | $406 | $16 |
| Allopurinol | 18 | $285 | $16 |
| Alfuzosin Hcl Er | 16 | $199 | $12 |
| Sulfamethoxazole-Trimethoprim | 35 | $170 | $5 |
| Levofloxacin | 24 | $147 | $6 |
| Fluconazole | 17 | $147 | $9 |
| Ketoconazole | 13 | $127 | $10 |
Year by year
| 2024 | 1,859 | 354 | 3% (55) | 12% | $284,222 |
| 2023 | 1,740 | 320 | 2% (30) | None | $288,848 |
| 2022 | 1,939 | 328 | 3% (56) | None | $287,390 |
| 2021 | 1,857 | 340 | 4% (71) | None | $254,946 |
| 2020 | 2,179 | 353 | 3% (63) | None | $345,430 |
| 2019 | 2,196 | 363 | 2% (40) | None | $472,816 |
| 2018 | 2,172 | 363 | 2% (40) | None | $451,847 |
| 2017 | 2,391 | 388 | 2% (45) | None | $467,649 |
| 2016 | 2,678 | 420 | 1% (37) | None | $414,695 |
| 2015 | 2,629 | 426 | 1% (28) | None | $470,161 |
| 2014 | 2,569 | 400 | 1% (34) | None | $405,847 |
| 2013 | 2,223 | 346 | 2% (48) | None | $269,473 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Gemtesa | 102 | $112,974 | $1,108 |
| Myrbetriq | 78 | $83,479 | $1,070 |
| Testosterone | 59 | $14,695 | $249 |
| Silodosin | 108 | $13,793 | $128 |
| Dutasteride | 129 | $9,446 | $73 |
| Tamsulosin | 365 | $8,106 | $22 |
| Estradiol | 65 | $6,191 | $95 |
| Bethanechol Chloride | 37 | $3,661 | $99 |
| Finasteride | 172 | $2,751 | $16 |
| Nitrofurantoin Mono-Macro | 56 | $2,288 | $41 |
| Desmopressin Acetate | 15 | $2,268 | $151 |
| Tadalafil | 36 | $2,023 | $56 |
| Doxazosin Mesylate | 53 | $1,626 | $31 |
| Levofloxacin | 44 | $1,105 | $25 |
| Ciprofloxacin | 63 | $582 | $9 |
| Cephalexin | 25 | $571 | $23 |
| Hydrocodone-Acetaminophen | 28 | $555 | $20 |
| Solifenacin | 11 | $476 | $43 |
| Allopurinol | 22 | $371 | $17 |
| Sulfamethoxazole-Trimethoprim | 35 | $342 | $10 |
| Oxybutynin Chloride Er | 17 | $294 | $17 |
| Fluconazole | 18 | $190 | $11 |
| Cyclobenzaprine | 11 | $150 | $14 |
| Ketoconazole | 14 | $100 | $7 |
2022: 29 drugs
| Myrbetriq | 104 | $90,920 | $874 |
| Gemtesa | 87 | $74,585 | $857 |
| Silodosin | 130 | $20,195 | $155 |
| Dutasteride | 128 | $12,009 | $94 |
| Tamsulosin | 383 | $8,653 | $23 |
| Imvexxy | 24 | $8,321 | $347 |
| Xyosted | 12 | $7,252 | $604 |
| Testosterone | 24 | $6,527 | $272 |
| Estradiol | 60 | $5,955 | $99 |
| Finasteride | 199 | $4,502 | $23 |
| Tadalafil | 32 | $4,310 | $135 |
| Toviaz | 11 | $4,280 | $389 |
| Bethanechol Chloride | 26 | $2,781 | $107 |
| Potassium Citrate Er | 13 | $2,303 | $177 |
| Nitrofurantoin Mono-Macro | 53 | $2,000 | $38 |
| Cholestyramine | 13 | $1,824 | $140 |
| Solifenacin | 22 | $1,682 | $76 |
| Doxazosin Mesylate | 51 | $1,543 | $30 |
| Bicalutamide | 15 | $1,007 | $67 |
| Hydrocodone-Acetaminophen | 51 | $876 | $17 |
| Cephalexin | 56 | $747 | $13 |
| Allopurinol | 28 | $582 | $21 |
| Ciprofloxacin | 61 | $575 | $9 |
| Ketoconazole | 13 | $536 | $41 |
| Levofloxacin | 51 | $475 | $9 |
| Oxybutynin Chloride Er | 18 | $424 | $24 |
| Sulfamethoxazole-Trimethoprim | 58 | $358 | $6 |
| Estradiol (Once Weekly) | 12 | $310 | $26 |
| Fluconazole | 16 | $137 | $9 |
2021: 28 drugs
| Myrbetriq | 145 | $115,412 | $796 |
| Gemtesa | 23 | $19,501 | $848 |
| Silodosin | 119 | $14,834 | $125 |
| Dutasteride | 116 | $10,023 | $86 |
| Estradiol | 62 | $8,237 | $133 |
| Tamsulosin | 367 | $7,705 | $21 |
| Testosterone | 24 | $7,635 | $318 |
| Imvexxy | 16 | $6,625 | $414 |
| Xyosted | 11 | $6,236 | $567 |
| Finasteride | 207 | $6,064 | $29 |
| Toviaz | 16 | $5,955 | $372 |
| Tadalafil | 31 | $5,823 | $188 |
| Bethanechol Chloride | 26 | $3,391 | $130 |
| Potassium Citrate Er | 18 | $2,485 | $138 |
| Nitrofurantoin Mono-Macro | 44 | $2,180 | $50 |
| Doxazosin Mesylate | 59 | $1,947 | $33 |
| Solifenacin | 21 | $1,536 | $73 |
| Desmopressin Acetate | 14 | $1,350 | $96 |
| Cholestyramine | 12 | $843 | $70 |
| Bicalutamide | 17 | $825 | $49 |
| Ketoconazole | 11 | $803 | $73 |
| Hydrocodone-Acetaminophen | 43 | $763 | $18 |
| Allopurinol | 35 | $637 | $18 |
| Cephalexin | 63 | $531 | $8 |
| Ciprofloxacin | 52 | $364 | $7 |
| Sulfamethoxazole-Trimethoprim | 47 | $333 | $7 |
| Levofloxacin | 41 | $328 | $8 |
| Tramadol | 23 | $57 | $2 |
2020: 33 drugs
| Myrbetriq | 194 | $142,916 | $737 |
| Silodosin | 131 | $17,744 | $135 |
| Testosterone | 35 | $17,054 | $487 |
| Toviaz | 27 | $10,693 | $396 |
| Tamsulosin | 436 | $9,965 | $23 |
| Dutasteride | 110 | $9,587 | $87 |
| Estradiol | 50 | $7,619 | $152 |
| Finasteride | 256 | $7,041 | $28 |
| Potassium Citrate Er | 22 | $3,861 | $176 |
| Doxazosin Mesylate | 65 | $2,852 | $44 |
| Dutasteride-Tamsulosin | 17 | $2,764 | $163 |
| Bethanechol Chloride | 25 | $2,687 | $107 |
| Desmopressin Acetate | 28 | $2,572 | $92 |
| Tadalafil | 43 | $2,327 | $54 |
| Nitrofurantoin Mono-Macro | 50 | $2,177 | $44 |
| Solifenacin | 22 | $2,109 | $96 |
| Bicalutamide | 23 | $1,399 | $61 |
| Oxybutynin Chloride Er | 19 | $937 | $49 |
| Nitrofurantoin | 11 | $914 | $83 |
| Cholestyramine | 13 | $913 | $70 |
| Terazosin | 20 | $843 | $42 |
| Hydrocodone-Acetaminophen | 48 | $813 | $17 |
| Allopurinol | 40 | $699 | $17 |
| Ketoconazole | 22 | $643 | $29 |
| Ciprofloxacin | 64 | $596 | $9 |
| Alfuzosin Hcl Er | 12 | $509 | $42 |
| Cephalexin | 64 | $507 | $8 |
| Sulfamethoxazole-Trimethoprim | 44 | $424 | $10 |
| Levofloxacin | 40 | $296 | $7 |
| Fluconazole | 15 | $168 | $11 |
| Venlafaxine Hcl Er | 11 | $90 | $8 |
| Furosemide | 16 | $59 | $4 |
| Tramadol | 12 | $42 | $4 |
2019: 36 drugs
| Zytiga | 13 | $143,694 | $11,053 |
| Myrbetriq | 147 | $104,989 | $714 |
| Testosterone | 45 | $33,806 | $751 |
| Vesicare | 37 | $24,157 | $653 |
| Silodosin | 108 | $21,860 | $202 |
| Rapaflo | 29 | $13,232 | $456 |
| Tamsulosin | 466 | $12,065 | $26 |
| Tadalafil | 54 | $11,354 | $210 |
| Finasteride | 270 | $8,543 | $32 |
| Toviaz | 26 | $8,463 | $325 |
| Dutasteride | 82 | $7,265 | $89 |
| Estradiol | 24 | $6,096 | $254 |
| Bethanechol Chloride | 46 | $5,615 | $122 |
| Potassium Citrate Er | 30 | $3,973 | $132 |
| Dutasteride-Tamsulosin | 24 | $3,872 | $161 |
| Nitrofurantoin Mono-Macro | 75 | $3,483 | $46 |
| Doxazosin Mesylate | 79 | $3,020 | $38 |
| Cholestyramine | 11 | $2,034 | $185 |
| Solifenacin | 12 | $1,959 | $163 |
| Oxybutynin Chloride Er | 23 | $1,222 | $53 |
| Desmopressin Acetate | 19 | $1,163 | $61 |
| Clobetasol Propionate | 19 | $1,039 | $55 |
| Allopurinol | 47 | $833 | $18 |
| Hydrocodone-Acetaminophen | 39 | $796 | $20 |
| Terazosin | 20 | $767 | $38 |
| Cephalexin | 53 | $602 | $11 |
| Bicalutamide | 11 | $543 | $49 |
| Alfuzosin Hcl Er | 17 | $492 | $29 |
| Ciprofloxacin | 52 | $428 | $8 |
| Sulfamethoxazole-Trimethoprim | 59 | $362 | $6 |
| Levofloxacin | 27 | $341 | $13 |
| Triamcinolone Acetonide | 11 | $226 | $21 |
| Ampicillin Trihydrate | 15 | $178 | $12 |
| Fluconazole | 11 | $151 | $14 |
| Prednisone | 13 | $112 | $9 |
| Triamterene-Hydrochlorothiazid | 12 | $71 | $6 |
2018: 34 drugs
| Myrbetriq | 122 | $86,964 | $713 |
| Rapaflo | 143 | $68,355 | $478 |
| Androgel | 33 | $48,029 | $1,455 |
| Vesicare | 63 | $41,460 | $658 |
| Cialis | 55 | $34,541 | $628 |
| Tamsulosin | 468 | $12,741 | $27 |
| Testosterone | 15 | $10,780 | $719 |
| Dutasteride | 95 | $9,654 | $102 |
| Finasteride | 306 | $8,029 | $26 |
| Tadalafil | 12 | $6,510 | $542 |
| Potassium Citrate Er | 32 | $5,560 | $174 |
| Toviaz | 15 | $5,284 | $352 |
| Estradiol | 18 | $4,668 | $259 |
| Dutasteride-Tamsulosin | 16 | $3,573 | $223 |
| Bethanechol Chloride | 31 | $3,273 | $106 |
| Doxazosin Mesylate | 82 | $2,983 | $36 |
| Tolterodine Tartrate Er | 13 | $2,933 | $226 |
| Cholestyramine | 12 | $2,223 | $185 |
| Oxybutynin Chloride Er | 41 | $2,208 | $54 |
| Nitrofurantoin Mono-Macro | 42 | $2,059 | $49 |
| Clobetasol Propionate | 16 | $1,481 | $93 |
| Allopurinol | 41 | $878 | $21 |
| Terazosin | 30 | $776 | $26 |
| Alfuzosin Hcl Er | 27 | $768 | $28 |
| Hydrocodone-Acetaminophen | 39 | $748 | $19 |
| Bicalutamide | 20 | $640 | $32 |
| Ciprofloxacin | 58 | $623 | $11 |
| Cephalexin | 65 | $555 | $9 |
| Amoxicillin-Clavulanate Potass | 15 | $312 | $21 |
| Sulfamethoxazole-Trimethoprim | 29 | $276 | $10 |
| Levofloxacin | 18 | $192 | $11 |
| Doxycycline Monohydrate | 11 | $110 | $10 |
| Fluconazole | 12 | $95 | $8 |
| Triamterene-Hydrochlorothiazid | 12 | $61 | $5 |
2017: 37 drugs
| Myrbetriq | 128 | $79,510 | $621 |
| Rapaflo | 153 | $62,807 | $411 |
| Androgel | 60 | $56,471 | $941 |
| Vesicare | 77 | $52,662 | $684 |
| Cialis | 68 | $36,177 | $532 |
| Tamsulosin | 447 | $14,902 | $33 |
| Dutasteride | 110 | $14,193 | $129 |
| Gelnique | 28 | $11,709 | $418 |
| Testosterone | 16 | $7,957 | $497 |
| Bethanechol Chloride | 48 | $7,076 | $147 |
| Finasteride | 281 | $7,074 | $25 |
| Potassium Citrate Er | 36 | $5,967 | $166 |
| Estrace | 16 | $5,108 | $319 |
| Tolterodine Tartrate Er | 25 | $4,864 | $195 |
| Nitrofurantoin Mono-Macro | 83 | $4,728 | $57 |
| Cardura Xl | 13 | $3,947 | $304 |
| Dutasteride-Tamsulosin | 20 | $3,781 | $189 |
| Oxybutynin Chloride Er | 49 | $3,107 | $63 |
| Doxazosin Mesylate | 71 | $2,915 | $41 |
| Cholestyramine | 13 | $2,315 | $178 |
| Clobetasol Propionate | 12 | $1,605 | $134 |
| Allopurinol | 64 | $1,491 | $23 |
| Nitrofurantoin | 23 | $1,230 | $53 |
| Bicalutamide | 41 | $1,072 | $26 |
| Alfuzosin Hcl Er | 40 | $1,038 | $26 |
| Hydrocodone-Acetaminophen | 45 | $868 | $19 |
| Oxybutynin Chloride | 13 | $864 | $66 |
| Ciprofloxacin | 77 | $834 | $11 |
| Terazosin | 26 | $509 | $20 |
| Testosterone Cypionate | 13 | $474 | $36 |
| Sulfamethoxazole-Trimethoprim | 44 | $396 | $9 |
| Amoxicillin-Clavulanate Potass | 15 | $383 | $26 |
| Trazodone | 12 | $336 | $28 |
| Cephalexin | 33 | $216 | $7 |
| Levofloxacin | 12 | $214 | $18 |
| Doxycycline Monohydrate | 13 | $130 | $10 |
| Triamterene-Hydrochlorothiazid | 13 | $74 | $6 |
2016: 45 drugs
| Myrbetriq | 110 | $67,709 | $616 |
| Rapaflo | 149 | $48,947 | $329 |
| Vesicare | 85 | $46,951 | $552 |
| Androgel | 36 | $32,739 | $909 |
| Cialis | 56 | $28,186 | $503 |
| Tamsulosin | 523 | $17,923 | $34 |
| Dutasteride | 130 | $15,700 | $121 |
| Avodart | 32 | $10,589 | $331 |
| Finasteride | 331 | $8,781 | $27 |
| Estrace | 27 | $8,080 | $299 |
| Enablex | 19 | $7,899 | $416 |
| Potassium Citrate Er | 50 | $6,924 | $138 |
| Testosterone | 12 | $6,032 | $503 |
| Tolterodine Tartrate Er | 31 | $5,232 | $169 |
| Oxybutynin Chloride Er | 84 | $5,211 | $62 |
| Nitrofurantoin Mono-Macro | 73 | $5,130 | $70 |
| Gelnique | 14 | $4,951 | $354 |
| Dutasteride-Tamsulosin | 21 | $4,819 | $229 |
| Cardura Xl | 17 | $4,498 | $265 |
| Clobetasol Propionate | 19 | $3,695 | $194 |
| Darifenacin Er | 13 | $3,455 | $266 |
| Bethanechol Chloride | 42 | $3,062 | $73 |
| Doxazosin Mesylate | 74 | $2,209 | $30 |
| Cholestyramine | 12 | $1,968 | $164 |
| Desmopressin Acetate | 15 | $1,882 | $125 |
| Bicalutamide | 28 | $1,415 | $51 |
| Nitrofurantoin | 21 | $1,366 | $65 |
| Ciprofloxacin | 127 | $1,318 | $10 |
| Allopurinol | 56 | $1,217 | $22 |
| Flutamide | 12 | $951 | $79 |
| Alfuzosin Hcl Er | 47 | $938 | $20 |
| Hydrocodone-Acetaminophen | 33 | $675 | $20 |
| Terazosin | 30 | $660 | $22 |
| Doxycycline Hyclate | 11 | $648 | $59 |
| Fluticasone Propionate | 15 | $637 | $42 |
| Oxybutynin Chloride | 11 | $430 | $39 |
| Sulfamethoxazole-Trimethoprim | 32 | $354 | $11 |
| Amoxicillin-Clavulanate Potass | 15 | $345 | $23 |
| Cephalexin | 42 | $338 | $8 |
| Levofloxacin | 26 | $275 | $11 |
| Trazodone | 12 | $238 | $20 |
| Ampicillin Trihydrate | 23 | $193 | $8 |
| Ondansetron Odt | 12 | $159 | $13 |
| Zolpidem | 12 | $77 | $6 |
| Diazepam | 17 | $73 | $4 |
2015: 39 drugs
| Myrbetriq | 99 | $56,207 | $568 |
| Vesicare | 112 | $42,527 | $380 |
| Rapaflo | 124 | $40,081 | $323 |
| Avodart | 110 | $36,427 | $331 |
| Lupron Depot | 12 | $35,094 | $2,925 |
| Androgel | 41 | $25,351 | $618 |
| Cialis | 54 | $21,535 | $399 |
| Tamsulosin | 549 | $20,187 | $37 |
| Elmiron | 22 | $17,396 | $791 |
| Enablex | 19 | $10,438 | $549 |
| Testim | 11 | $8,618 | $783 |
| Estrace | 28 | $8,292 | $296 |
| Potassium Citrate Er | 53 | $6,824 | $129 |
| Oxybutynin Chloride Er | 90 | $6,162 | $68 |
| Finasteride | 309 | $5,665 | $18 |
| Nitrofurantoin Mono-Macro | 64 | $4,867 | $76 |
| Clobetasol Propionate | 23 | $4,485 | $195 |
| Tolterodine Tartrate Er | 17 | $3,792 | $223 |
| Cardura Xl | 24 | $3,567 | $149 |
| Dutasteride | 13 | $3,167 | $244 |
| Bethanechol Chloride | 50 | $2,931 | $59 |
| Nitrofurantoin | 29 | $2,258 | $78 |
| Doxazosin Mesylate | 57 | $2,119 | $37 |
| Cholestyramine | 12 | $1,672 | $139 |
| Allopurinol | 74 | $1,513 | $20 |
| Ciprofloxacin | 130 | $1,407 | $11 |
| Bicalutamide | 39 | $1,396 | $36 |
| Flutamide | 11 | $915 | $83 |
| Amoxicillin-Clavulanate Potass | 31 | $841 | $27 |
| Testosterone Cypionate | 11 | $496 | $45 |
| Alfuzosin Hcl Er | 26 | $485 | $19 |
| Oxybutynin Chloride | 11 | $453 | $41 |
| Terazosin | 27 | $434 | $16 |
| Sulfamethoxazole-Trimethoprim | 42 | $345 | $8 |
| Hydrocodone-Acetaminophen | 24 | $337 | $14 |
| Ampicillin Trihydrate | 31 | $245 | $8 |
| Temazepam | 11 | $197 | $18 |
| Cephalexin | 19 | $170 | $9 |
| Lidocaine | 12 | $147 | $12 |
2014: 39 drugs
| Avodart | 209 | $52,669 | $252 |
| Vesicare | 124 | $37,478 | $302 |
| Myrbetriq | 81 | $35,014 | $432 |
| Rapaflo | 155 | $32,637 | $211 |
| Lupron Depot | 12 | $24,702 | $2,059 |
| Androgel | 36 | $20,695 | $575 |
| Elmiron | 18 | $17,278 | $960 |
| Cialis | 49 | $17,098 | $349 |
| Tamsulosin | 507 | $13,387 | $26 |
| Enablex | 22 | $8,785 | $399 |
| Potassium Citrate Er | 70 | $6,859 | $98 |
| Toviaz | 14 | $6,841 | $489 |
| Finasteride | 249 | $5,988 | $24 |
| Jalyn | 11 | $4,427 | $402 |
| Oxybutynin Chloride Er | 61 | $4,325 | $71 |
| Trospium Chloride Er | 14 | $3,380 | $241 |
| Cardura Xl | 23 | $3,261 | $142 |
| Estrace | 16 | $3,259 | $204 |
| Cholestyramine | 12 | $2,563 | $214 |
| Nitrofurantoin Mono-Macro | 40 | $2,520 | $63 |
| Bicalutamide | 39 | $1,975 | $51 |
| Bethanechol Chloride | 58 | $1,920 | $33 |
| Doxazosin Mesylate | 57 | $1,837 | $32 |
| Nitrofurantoin | 17 | $1,559 | $92 |
| Clobetasol Propionate | 28 | $1,214 | $43 |
| Testosterone Cypionate | 17 | $1,194 | $70 |
| Amox Tr-Potassium Clavulanate | 19 | $1,138 | $60 |
| Ciprofloxacin | 108 | $997 | $9 |
| Allopurinol | 73 | $934 | $13 |
| Doxycycline Hyclate | 17 | $867 | $51 |
| Alfuzosin Hcl Er | 21 | $820 | $39 |
| Hydrocodone-Acetaminophen | 31 | $602 | $19 |
| Zaleplon | 14 | $548 | $39 |
| Sulfamethoxazole-Trimethoprim | 61 | $524 | $9 |
| Oxybutynin Chloride | 11 | $495 | $45 |
| Terazosin | 23 | $368 | $16 |
| Ketoconazole | 14 | $236 | $17 |
| Zolpidem | 16 | $124 | $8 |
| Cephalexin | 17 | $107 | $6 |
2013: 36 drugs
| Avodart | 205 | $46,609 | $227 |
| Vesicare | 114 | $32,632 | $286 |
| Lupron Depot | 15 | $20,179 | $1,345 |
| Androgel | 35 | $18,772 | $536 |
| Rapaflo | 86 | $16,701 | $194 |
| Elmiron | 14 | $13,305 | $950 |
| Tamsulosin | 435 | $11,248 | $26 |
| Myrbetriq | 29 | $10,518 | $363 |
| Enablex | 32 | $8,824 | $276 |
| Testim | 19 | $6,753 | $355 |
| Finasteride | 196 | $6,419 | $33 |
| Potassium Citrate | 68 | $5,526 | $81 |
| Jalyn | 14 | $4,872 | $348 |
| Oxybutynin Chloride Er | 45 | $4,303 | $96 |
| Nitrofurantoin Mono-Macro | 38 | $3,764 | $99 |
| Bethanechol Chloride | 48 | $3,181 | $66 |
| Trospium Chloride Er | 11 | $3,056 | $278 |
| Cholestyramine | 14 | $2,688 | $192 |
| Cardura Xl | 21 | $2,543 | $121 |
| Bicalutamide | 31 | $2,366 | $76 |
| Estrace | 16 | $2,300 | $144 |
| Doxazosin Mesylate | 77 | $1,544 | $20 |
| Cialis | 12 | $1,516 | $126 |
| Ciprofloxacin | 135 | $1,098 | $8 |
| Alfuzosin | 21 | $1,083 | $52 |
| Nitrofurantoin | 20 | $891 | $45 |
| Testosterone Cypionate | 11 | $878 | $80 |
| Hydrocodone-Acetaminophen | 45 | $729 | $16 |
| Allopurinol | 75 | $568 | $8 |
| Amox Tr-Potassium Clavulanate | 11 | $447 | $41 |
| Terazosin | 22 | $410 | $19 |
| Zaleplon | 14 | $398 | $28 |
| Sulfamethoxazole-Trimethoprim | 38 | $373 | $10 |
| Clobetasol Propionate | 13 | $275 | $21 |
| Furosemide | 24 | $144 | $6 |
| Ampicillin Trihydrate | 14 | $107 | $8 |
Money from drug and device companies
$1,713 in 2025
| 2025 | 14 | 59 | None | $1,713 |
| 2024 | 12 | 35 | None | $960 |
| 2023 | 13 | 38 | None | $988 |
| 2022 | 15 | 51 | None | $1,312 |
| 2021 | 14 | 29 | None | $585 |
| 2020 | 12 | 24 | None | $503 |
| 2019 | 16 | 55 | None | $1,112 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sumitomo Pharma America | Gemtesa | $943 | 31 payments
|
| Accord Healthcare | Camcevi | $123 | 5 payments
|
| Ferring Pharmaceuticals | Adstiladrin | $116 | 1 payment
|
| Abbvie | Botox | $99 | 4 payments
|
| Janssen Biotech | Erleada | $65 | 2 payments
|
| Progenics Pharmaceuticals | Pylarify | $62 | 3 payments
|
See all 59 published payments
| Teleflex | Meals · 2025-12-30 | Urolift | $25 |
| Alnylam Pharmaceuticals | Meals · 2025-12-11 | Givlaari | $31 |
| Abbvie | Meals · 2025-12-09 | Botox | $26 |
| 180 Medical | Meals · 2025-11-05 | None | $22 |
| Sumitomo Pharma America | Meals · 2025-11-02 | Gemtesa | $45 |
| Verity Pharmaceuticals | Meals · 2025-10-29 | Tlando | $15 |
| Janssen Biotech | Meals · 2025-10-28 | Erleada | $31 |
| Sumitomo Pharma America | Meals · 2025-10-24 | Gemtesa | $38 |
| Sumitomo Pharma America | Meals · 2025-10-16 | Gemtesa | $36 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-13 | None | $25 |
| Sumitomo Pharma America | Meals · 2025-10-09 | Gemtesa | $36 |
| Verity Pharmaceuticals | Meals · 2025-10-07 | Tlando | $24 |
| Accord Healthcare | Meals · 2025-10-01 | Camcevi | $24 |
| Sumitomo Pharma America | Meals · 2025-09-25 | Gemtesa | $40 |
| Janssen Biotech | Meals · 2025-09-24 | Erleada | $34 |
| Sumitomo Pharma America | Meals · 2025-09-19 | Gemtesa | $28 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-09-16 | None | $28 |
| Sumitomo Pharma America | Meals · 2025-09-05 | Gemtesa | $38 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-09-02 | Nubeqa | $22 |
| Progenics Pharmaceuticals | Meals · 2025-08-26 | Pylarify | $26 |
| Sumitomo Pharma America | Meals · 2025-08-13 | Gemtesa | $38 |
| Verity Pharmaceuticals | Meals · 2025-08-13 | Tlando | $23 |
| Astellas Pharma US | Meals · 2025-08-12 | Xtandi | $25 |
| Sumitomo Pharma America | Meals · 2025-07-31 | Gemtesa | $35 |
| Sumitomo Pharma America | Meals · 2025-07-22 | Gemtesa | $14 |
| Accord Healthcare | Meals · 2025-07-17 | Camcevi | $26 |
| Sumitomo Pharma America | Meals · 2025-07-09 | Gemtesa | $36 |
| Progenics Pharmaceuticals | Meals · 2025-07-09 | Pylarify | $21 |
| Sumitomo Pharma America | Meals · 2025-06-29 | Gemtesa | $10 |
| Sumitomo Pharma America | Meals · 2025-06-19 | Gemtesa | $35 |
| Sumitomo Pharma America | Meals · 2025-06-09 | Gemtesa | $16 |
| Accord Healthcare | Meals · 2025-06-04 | Camcevi | $22 |
| Sumitomo Pharma America | Meals · 2025-05-28 | Gemtesa | $39 |
| Abbvie | Meals · 2025-05-21 | Botox | $25 |
| Sumitomo Pharma America | Meals · 2025-05-16 | Gemtesa | $17 |
| Sumitomo Pharma America | Meals · 2025-05-09 | Gemtesa | $31 |
| Sumitomo Pharma America | Meals · 2025-05-02 | Gemtesa | $41 |
| Sumitomo Pharma America | Meals · 2025-04-25 | Gemtesa | $41 |
| Ferring Pharmaceuticals | Meals · 2025-04-23 | Adstiladrin | $116 |
| Abbvie | Meals · 2025-04-18 | Botox | $24 |
| Progenics Pharmaceuticals | Meals · 2025-04-14 | Pylarify | $15 |
| Sumitomo Pharma America | Meals · 2025-04-07 | Gemtesa | $39 |
| Accord Healthcare | Meals · 2025-04-03 | Camcevi | $24 |
| Sumitomo Pharma America | Meals · 2025-03-26 | Gemtesa | $26 |
| Abbvie | Meals · 2025-03-24 | Botox | $23 |
| Sumitomo Pharma America | Meals · 2025-03-19 | Gemtesa | $42 |
| Telix Pharmaceuticals | Meals · 2025-03-14 | Illuccix | $26 |
| Sumitomo Pharma America | Meals · 2025-03-12 | Gemtesa | $40 |
| Telix Pharmaceuticals | Meals · 2025-03-02 | Illuccix | $20 |
| Sumitomo Pharma America | Education · 2025-02-28 | Gemtesa | $5 |
| Sumitomo Pharma America | Meals · 2025-02-27 | Gemtesa | $26 |
| Accord Healthcare | Meals · 2025-02-19 | Camcevi | $27 |
| Sumitomo Pharma America | Meals · 2025-02-14 | Gemtesa | $36 |
| Astellas Pharma US | Meals · 2025-02-11 | Xtandi | $20 |
| Sumitomo Pharma America | Meals · 2025-02-06 | Gemtesa | $23 |
| Sumitomo Pharma America | Meals · 2025-02-06 | Gemtesa | $18 |
| Sumitomo Pharma America | Meals · 2025-01-29 | Gemtesa | $28 |
| Sumitomo Pharma America | Meals · 2025-01-14 | Gemtesa | $9 |
| Sumitomo Pharma America | Meals · 2025-01-09 | Gemtesa | $37 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $960
| Sumitomo Pharma America | Gemtesa | $311 | 10 payments
|
| Astellas Pharma US | Xtandi | $242 | 9 payments
|
| Blue Earth Diagnostics | Posluma | $94 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $66 | 3 payments
|
| Immunitybio | Anktiva | $63 | 2 payments
|
| Janssen Biotech | Erleada | $47 | 2 payments
|
| Dendreon Pharmaceuticals | Provenge | $32 | 1 payment
|
| Olympus America | Itind System | $30 | 1 payment
|
| Laborie Medical Technologies | Optilume Bph Drug Coated Balloon Catheter | $26 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $19 | 1 payment
|
| Antares Pharma | Xyosted | $15 | 1 payment
|
| Abbvie | Lupron Depot | $15 | 1 payment
|
2023: $988
| Astellas Pharma US | Myrbetriq | $310 | 15 payments
|
| Sumitomo Pharma America | Gemtesa | $235 | 7 payments
|
| Dendreon Pharmaceuticals | Provenge | $161 | 5 payments
|
| Janssen Biotech | Erleada | $64 | 2 payments
|
| Ethicon US | Vistaseal | $38 | 1 payment
|
| Amgen | Xgeva | $35 | 1 payment
|
| Tolmar | Jatenzo | $28 | 1 payment
|
| Endo Pharmaceuticals | Aveed | $25 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $20 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $20 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $18 | 1 payment
|
| Antares Pharma | Nocdurna | $17 | 1 payment
|
| Supernus Pharmaceuticals | Xyosted | $16 | 1 payment
|
2022: $1,312
| Astellas Pharma US | Myrbetriq | $555 | 20 payments
|
| Urovant Sciences | Gemtesa | $275 | 9 payments
|
| Amgen | Xgeva | $93 | 3 payments
|
| Dendreon Pharmaceuticals | Provenge | $75 | 3 payments
|
| Accord Healthcare | Camcevi | $54 | 3 payments
|
| Progenics Pharmaceuticals | Pylarify | $49 | 2 payments
|
| Allergan | Botox | $47 | 3 payments
|
| UroGen Pharma | None | $27 | 1 payment
|
| Abbvie | Lupron Depot | $27 | 1 payment
|
| Myriad Genetic Laboratories | Brac Cdx | $21 | 1 payment
|
| 180 Medical | Gentlecath | $21 | 1 payment
|
| Hollister | Infyna Chic | $19 | 1 payment
|
| Janssen Biotech | Erleada | $19 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $18 | 1 payment
|
| Antares Pharma | Nocdurna | $15 | 1 payment
|
2021: $585
| Astellas Pharma US | Xtandi | $233 | 12 payments
|
| 180 Medical | Gentlecath | $66 | 3 payments
|
| Amgen | Prolia | $57 | 2 payments
|
| Clarus Therapeutics | Jatenzo | $33 | 2 payments
|
| Myriad Genetic Laboratories | Prolaris | $25 | 1 payment
|
| AbbVie | Lupron Depot | $23 | 1 payment
|
| TOLMAR Pharmaceuticals | Eligard | $23 | 1 payment
|
| TherapeuticsMD | Imvexxy | $21 | 1 payment
|
| Urogen Pharma | Jelmyto | $21 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $20 | 1 payment
|
| AngioDynamics | Nanoknife | $17 | 1 payment
|
| Axonics | Axonics R-Snm System | $17 | 1 payment
|
| Antares Pharma | Xyosted | $17 | 1 payment
|
| Allergan | Botox | $12 | 1 payment
|
2020: $503
| Astellas Pharma US | Myrbetriq | $207 | 7 payments
|
| Antares Pharma | Otrexup | $59 | 3 payments
|
| Coloplast | Speedicath | $48 | 3 payments
|
| Amgen | Prolia | $40 | 2 payments
|
| 180 Medical | Speedicath | $31 | 2 payments
|
| AbbVie | Lupron Depot | $24 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $22 | 1 payment
|
| TOLMAR Pharmaceuticals | Eligard | $17 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $17 | 1 payment
|
| Pfizer | Xtandi | $14 | 1 payment
|
| Myriad Genetic Laboratories | Bracanalysis Cdx | $13 | 1 payment
|
| Janssen Biotech | Erleada | $11 | 1 payment
|
2019: $1,112
| Amgen | Prolia | $250 | 10 payments
|
| Astellas Pharma US | Myrbetriq | $244 | 13 payments
|
| Pfizer | Xtandi | $90 | 5 payments
|
| Dendreon Pharmaceuticals | Provenge | $85 | 3 payments
|
| AbbVie | Lupron Depot | $62 | 3 payments
|
| Antares Pharma | Xyosted | $61 | 3 payments
|
| Coloplast | Speedicath | $60 | 4 payments
|
| TOLMAR Pharmaceuticals | Eligard | $43 | 2 payments
|
| Janssen Biotech | Erleada | $43 | 3 payments
|
| TherapeuticsMD | Imvexxy | $41 | 2 payments
|
| 180 Medical | Gentlecath | $35 | 2 payments
|
| Endo Pharmaceuticals | Xiaflex | $24 | 1 payment
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $19 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $19 | 1 payment
|
| Photocure | Cysview | $18 | 1 payment
|
| Zyla Life Sciences | Zorvolex | $16 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1922156157
- Licence
- CA G-39344California G39344: Current · expires 2029-02-28
- Trained
- University of Washington School of Medicine, 1971
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 00G303440
- Taxonomy
- Urology (208800000X)
- Mailing address
- 2550 Samaritan Dr Ste D, San Jose, CA, 95124
- NPI first listed
- 2007-01-05
- NPI last updated
- 2007-07-09
This is when the NPI record was last certified, not a medical board exam.